EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

A pleuromutilin–ciprofloxacin hybrid exhibits potent activity against Streptococcus suis

Guiyu Zhou, Feike Zhao, Xirui Jia, Xiaoyu Wang, Cunchun Dai, Liangzhu Chen, Binghu Fang

Frontiers in Cellular and Infection Microbiology · 14.08.2026 · 16

DOI: 10.3389/fcimb.2026.1920241 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Frontiers in Cellular and Infection Microbiology, online erschienen am 14.08.2026. Verfasst von Guiyu Zhou und 6 weiteren Autor:innen. Beteiligte Einrichtung: College of Veterinary Medicine, South China Agricultural University, Guangzhou, Guangdong, China. Hauptthemen laut MEDLINE: Streptococcus suis, Anti-Bacterial Agents, Diterpenes, Ciprofloxacin. Die Arbeit nennt 36 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Key Research and Development Program of China.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The emergence and dissemination of antimicrobial resistance in Streptococcus suis , an important zoonotic pathogen, have created an urgent demand for new therapeutic agents with improved antibacterial efficacy. To address this challenge, we previously designed and synthesized a novel hybrid molecule, PHC, by linking ciprofloxacin to a pleuromutilin derivative via an L-homocysteine bridge. Although preliminary evaluations indicated favourable antibacterial activity, the antimicrobial effect of PHC against S. suis and its mechanism of action have not yet been systematically characterized. Therefore, the present study aimed to investigate the antibacterial activity of PHC against S. suis and elucidate its underlying antibacterial mechanisms.

Methods

The antibacterial efficacy of PHC was assessed through time-kill kinetics and a murine infection model. Molecular docking was conducted to predict the interactions between PHC and its potential molecular targets, and RT–qPCR analysis was performed to evaluate the effects of PHC on genes associated with DNA replication, ribosomal function, oxidative stress, and energy metabolism in S. suis . Biofilm formation was quantified using crystal violet staining. In addition, DAPI/PI staining and DiSC3(5) fluorescence assays were employed to assess bacterial membrane integrity and membrane potential, respectively. Changes in intracellular ATP levels and ROS production were further measured to characterize the antibacterial mode of action of PHC.

Results

PHC exhibited potent antibacterial activity against S. suis both in vitro and in vivo . Molecular docking and transcriptional analyses suggested that PHC may interfere with bacterial DNA replication and protein synthesis by affecting topoisomerase- and ribosome-associated pathways. In addition, PHC disrupted membrane integrity and membrane potential, altered cellular energy metabolism and promoted oxidative stress responses. Furthermore, PHC demonstrated favourable therapeutic efficacy and biosafety in a murine infection model.

Conclusion

PHC exhibits potent antibacterial activity against S. suis through interference with DNA replication- and protein synthesis-related processes, accompanied by enhanced bacterial stress responses and disruption of membrane integrity and cellular homeostasis. This study provides a theoretical basis for the further development of PHC and offers valuable insights for the design of novel hybrid antibacterial agents against S. suis .

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Streptococcus suisAnti-Bacterial AgentsDiterpenesCiprofloxacinPleuromutilinsAnimalsStreptococcal InfectionsPolycyclic CompoundsMolecular Docking SimulationMicrobial Sensitivity TestsMiceBiofilmsDisease Models, AnimalReactive Oxygen SpeciesAdenosine Triphosphate

Stichwörter der Autor:innen

Streptococcus suisantibacterial mechanismantimicrobial candidateantimicrobial resistancehybrid antibacterial agent

Substanzen

PleuromutilinsAnti-Bacterial AgentsDiterpenesPolycyclic CompoundsCiprofloxacinReactive Oxygen SpeciesAdenosine Triphosphate

Autor:innen und Institutionen

  • College of Veterinary Medicine, South China Agricultural University, Guangzhou, Guangdong, China.
  • Guangdong Wenshi Dahuanong Biotechnology Co, Ltd, Yunfu, Guangdong, China.

Förderung

  • National Key Research and Development Program of China

Zitieren

APA

Zhou, G., Zhao, F., Jia, X., Wang, X., Dai, C., Chen, L., & Fang, B. (2026). A pleuromutilin–ciprofloxacin hybrid exhibits potent activity against Streptococcus suis. Frontiers in Cellular and Infection Microbiology, 16. https://doi.org/10.3389/fcimb.2026.1920241

Vancouver

Zhou G, Zhao F, Jia X, Wang X, Dai C, Chen L, et al. A pleuromutilin–ciprofloxacin hybrid exhibits potent activity against Streptococcus suis. Frontiers in Cellular and Infection Microbiology. 2026;16. doi:10.3389/fcimb.2026.1920241

BibTeX
@article{Zhou2026,
  author = {Zhou, Guiyu and Zhao, Feike and Jia, Xirui and Wang, Xiaoyu and Dai, Cunchun and Chen, Liangzhu and Fang, Binghu},
  title = {A pleuromutilin–ciprofloxacin hybrid exhibits potent activity against Streptococcus suis},
  journal = {Frontiers in Cellular and Infection Microbiology},
  year = {2026},
  volume = {16},
  doi = {10.3389/fcimb.2026.1920241}
}
Kostenlos starten →